EFFICACY OF BRODALUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A NETWORK META-ANALYSIS

被引：0
|
作者：
Xue, W. [1 ]
Barbeau, M. [2 ]
Khoudigian-Sinani, S. [3 ]
Gray, E. [1 ]
Saharia, P. [4 ]
Frieder, D. [2 ]
机构：
[1] IQVIA, London, England
[2] Valeant Canada LP, Laval, ON, Canada
[3] IQVIA, Mississauga, ON, Canada
[4] IQVIA, Gurgaon, India
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1624
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS3
引用
收藏
页码：S239 / S239
页数：1
相关论文
共 50 条
  • [41] Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis
    Geng, Wenjun
    Zhao, Jianhua
    Fu, Jixing
    Zhang, Huamin
    Qiao, Shaohua
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (06) : 5085 - 5095
  • [42] Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
    Andrew Blauvelt
    Melinda Gooderham
    Christopher E. M. Griffiths
    April W. Armstrong
    Baojin Zhu
    Russel Burge
    Gaia Gallo
    Jiaying Guo
    Alyssa Garrelts
    Mark Lebwohl
    Dermatology and Therapy, 2022, 12 : 727 - 740
  • [43] Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
    Blauvelt, Andrew
    Gooderham, Melinda
    Griffiths, Christopher E. M.
    Armstrong, April W.
    Zhu, Baojin
    Burge, Russel
    Gallo, Gaia
    Guo, Jiaying
    Garrelts, Alyssa
    Lebwohl, Mark
    DERMATOLOGY AND THERAPY, 2022, 12 (03) : 727 - 740
  • [44] Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
    Coimbra, Susana
    Figueiredo, Americo
    Santos-Silva, Alice
    CORE EVIDENCE, 2014, 9 : 89 - 97
  • [45] Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis
    Yamauchi, Paul
    Elewski, Boni
    Wu, Jashin J.
    Rastogi, Shipra
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB119 - AB119
  • [46] Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
    Papp, Kim
    Menter, Alan
    Strober, Bruce
    Kricorian, Greg
    Thompson, ElizabethH. Z.
    Milmont, Cassandra E.
    Nirula, Ajay
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (03) : 436 - U100
  • [47] The importance of assessing and adjusting for heterogeneity in network meta-analysis: A case study assessing the comparative efficacy of treatments for moderate-to-severe psoriasis
    Cameron, Chris
    Hutton, Brian
    Varu, Abhishek
    Druchok, Cheryl
    McElligott, Sean
    Schubert, Agata
    Situ, Aaron
    Villacorta, Reggie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB288 - AB288
  • [48] Long-term efficacy of brodalumab in ustekinumab-responsive patients with moderate-to-severe psoriasis
    Green, Lawrence
    Hsu, Sylvia
    Papp, Kim A.
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB181 - AB181
  • [49] Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in two pivotal phase 3 clinical trials
    Lebwohl, Mark
    Papp, Kim A.
    Tyring, Stephen
    Krueger, James
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB180 - AB180
  • [50] Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
    Yeung, Jensen
    Ladda, Matthew
    Piguet, Vincent
    SAGE OPEN MEDICAL CASE REPORTS, 2020, 8
12345